Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis
Authors:
- 30 November 2022
- journal article
- research article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 20 (1) , 51-64
Abstract
Boosting tumor immunosurveillance with vaccines has been proven to be a feasible and cost-effective strategy to fight cancer. Although major breakthroughs have been achieved in preventative tumor vaccines targeting oncogenic viruses, limited advances have been made in curative vaccines for virus-irrelevant malignancies. Accumulating evidence suggests that preconditioning tumor cells with certain cytotoxic drugs can generate whole-cell tumor vaccines with strong prophylactic activities. However, the immunogenicity of these vaccines is not sufficient to restrain the outgrowth of existing tumors. In this study, we identified arsenic trioxide (ATO) as a wide-spectrum cytotoxic and highly immunogenic drug through multiparameter screening. ATO preconditioning could generate whole-cell tumor vaccines with potent antineoplastic effects in both prophylactic and therapeutic settings. The tumor-preventive or tumor-suppressive benefits of these vaccines relied on CD8+ T cells and type I and II interferon signaling and could be linked to the release of immunostimulatory danger molecules. Unexpectedly, following ATO-induced oxidative stress, multiple cell death pathways were activated, including autophagy, apoptosis, necroptosis, and ferroptosis. CRISPR‒Cas9-mediated knockout of cell death executors revealed that the absence of Rip3, Mlkl, or Acsl4 largely abolished the efficacy of ATO-based prophylactic and therapeutic cancer vaccines. This therapeutic failure could be rescued by coadministration of danger molecule analogs. In addition, PD-1 blockade synergistically improved the therapeutic efficacy of ATO-based cancer vaccines by augmenting local IFN-γ production.Keywords
This publication has 50 references indexed in Scilit:
- Sevoflurane Combined with ATP Activates Caspase-1 and Triggers Caspase-1-Dependent Pyroptosis in Murine J774 MacrophagesInflammation, 2012
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer VaccineClinical Cancer Research, 2011
- Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization programHepatology, 2011
- Chemotherapy and radiotherapy: Cryptic anticancer vaccinesSeminars in Immunology, 2010
- Whole tumor antigen vaccinesSeminars in Immunology, 2010
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune ActivationClinical Cancer Research, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 2006
- Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trialInvestigational New Drugs, 2006
- Caspase-dependent immunogenicity of doxorubicin-induced tumor cell deathJournal of Experimental Medicine, 2005